ATE203511T1 - Selektive beta3-adrenergische agonisten - Google Patents
Selektive beta3-adrenergische agonistenInfo
- Publication number
- ATE203511T1 ATE203511T1 AT96306850T AT96306850T ATE203511T1 AT E203511 T1 ATE203511 T1 AT E203511T1 AT 96306850 T AT96306850 T AT 96306850T AT 96306850 T AT96306850 T AT 96306850T AT E203511 T1 ATE203511 T1 AT E203511T1
- Authority
- AT
- Austria
- Prior art keywords
- adrenergic agonists
- diabetes
- type
- selective
- beta3
- Prior art date
Links
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US408395P | 1995-09-21 | 1995-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE203511T1 true ATE203511T1 (de) | 2001-08-15 |
Family
ID=21709054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96306850T ATE203511T1 (de) | 1995-09-21 | 1996-09-20 | Selektive beta3-adrenergische agonisten |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0764632B1 (de) |
| JP (1) | JPH11513376A (de) |
| KR (1) | KR19990045727A (de) |
| CN (1) | CN1202106A (de) |
| AT (1) | ATE203511T1 (de) |
| AU (1) | AU715493B2 (de) |
| BR (1) | BR9610481A (de) |
| CA (1) | CA2232090A1 (de) |
| CZ (1) | CZ82198A3 (de) |
| DE (1) | DE69614057T2 (de) |
| DK (1) | DK0764632T3 (de) |
| EA (1) | EA001217B1 (de) |
| ES (1) | ES2158996T3 (de) |
| GR (1) | GR3036963T3 (de) |
| HU (1) | HUP9802257A3 (de) |
| IL (1) | IL123677A0 (de) |
| NO (1) | NO981204L (de) |
| NZ (1) | NZ318712A (de) |
| PL (1) | PL325865A1 (de) |
| PT (1) | PT764632E (de) |
| SI (1) | SI0764632T1 (de) |
| TR (1) | TR199800521T1 (de) |
| WO (1) | WO1997010822A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2381397A (en) * | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| WO1999029672A1 (en) | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | SELECTIVE β3 ADRENERGIC AGONISTS |
| PE20000415A1 (es) * | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
| AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| WO2001035947A2 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| WO2001036412A1 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| FR2809725B1 (fr) * | 2000-06-06 | 2004-05-07 | Sanofi Synthelabo | Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant |
| FR2817257B1 (fr) * | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| WO2003072573A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| EP1478625A1 (de) | 2002-02-27 | 2004-11-24 | Pfizer Products Inc. | Zur herstellung von agonisten des beta-3-adrenergen rezeptors geeignete verfahren und zwischenprodukte |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498999A (en) * | 1966-04-20 | 1970-03-03 | Bristol Myers Co | 1-phenoxy and substituted phenoxy-3-(5-tetrazolyl) propanes |
| GB1433920A (en) * | 1973-10-01 | 1976-04-28 | Ici Ltd | Alkanolamine derivatives |
| US4080471A (en) * | 1976-06-25 | 1978-03-21 | Aktiebolaget Hassle | Use of substituted isopropylaminopropanols for inducing inotropic effects of the human heart |
| FR2640969B1 (de) * | 1988-12-23 | 1991-11-22 | Midy Spa | |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| EP0627407A1 (de) * | 1993-05-28 | 1994-12-07 | MIDY S.p.A. | (7S)-7-(2R)-2(3-Chlorophenyl)-2-hydroxethylamino-5,6,7,8-Tetrahydronaphthalen-2-yloxy-Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzung |
| US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
-
1996
- 1996-09-20 ES ES96306850T patent/ES2158996T3/es not_active Expired - Lifetime
- 1996-09-20 EP EP96306850A patent/EP0764632B1/de not_active Expired - Lifetime
- 1996-09-20 PL PL96325865A patent/PL325865A1/xx unknown
- 1996-09-20 DE DE69614057T patent/DE69614057T2/de not_active Expired - Fee Related
- 1996-09-20 AT AT96306850T patent/ATE203511T1/de not_active IP Right Cessation
- 1996-09-20 AU AU70770/96A patent/AU715493B2/en not_active Ceased
- 1996-09-20 TR TR1998/00521T patent/TR199800521T1/xx unknown
- 1996-09-20 DK DK96306850T patent/DK0764632T3/da active
- 1996-09-20 SI SI9630344T patent/SI0764632T1/xx unknown
- 1996-09-20 KR KR1019980701968A patent/KR19990045727A/ko not_active Withdrawn
- 1996-09-20 PT PT96306850T patent/PT764632E/pt unknown
- 1996-09-20 BR BR9610481A patent/BR9610481A/pt not_active Application Discontinuation
- 1996-09-20 CN CN96198229A patent/CN1202106A/zh active Pending
- 1996-09-20 HU HU9802257A patent/HUP9802257A3/hu unknown
- 1996-09-20 NZ NZ318712A patent/NZ318712A/xx unknown
- 1996-09-20 WO PCT/US1996/015103 patent/WO1997010822A1/en not_active Ceased
- 1996-09-20 JP JP9512920A patent/JPH11513376A/ja active Pending
- 1996-09-20 IL IL12367796A patent/IL123677A0/xx unknown
- 1996-09-20 EA EA199800317A patent/EA001217B1/ru not_active IP Right Cessation
- 1996-09-20 CA CA002232090A patent/CA2232090A1/en not_active Abandoned
- 1996-09-20 CZ CZ98821A patent/CZ82198A3/cs unknown
-
1998
- 1998-03-17 NO NO981204A patent/NO981204L/no not_active Application Discontinuation
-
2001
- 2001-10-22 GR GR20010401833T patent/GR3036963T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2232090A1 (en) | 1997-03-27 |
| AU7077096A (en) | 1997-04-09 |
| WO1997010822A1 (en) | 1997-03-27 |
| GR3036963T3 (en) | 2002-01-31 |
| NO981204D0 (no) | 1998-03-17 |
| PT764632E (pt) | 2001-12-28 |
| DK0764632T3 (da) | 2001-09-24 |
| TR199800521T1 (xx) | 1998-06-22 |
| MX9802097A (es) | 1998-08-30 |
| SI0764632T1 (en) | 2001-12-31 |
| CN1202106A (zh) | 1998-12-16 |
| JPH11513376A (ja) | 1999-11-16 |
| HUP9802257A2 (hu) | 1999-02-01 |
| DE69614057T2 (de) | 2002-03-14 |
| ES2158996T3 (es) | 2001-09-16 |
| EP0764632A3 (de) | 1997-12-10 |
| BR9610481A (pt) | 1999-05-11 |
| EA199800317A1 (ru) | 1998-10-29 |
| KR19990045727A (ko) | 1999-06-25 |
| EP0764632B1 (de) | 2001-07-25 |
| HUP9802257A3 (en) | 1999-04-28 |
| NZ318712A (en) | 1999-08-30 |
| IL123677A0 (en) | 1998-10-30 |
| EA001217B1 (ru) | 2000-12-25 |
| AU715493B2 (en) | 2000-02-03 |
| NO981204L (no) | 1998-04-17 |
| DE69614057D1 (de) | 2001-08-30 |
| CZ82198A3 (cs) | 1998-07-15 |
| EP0764632A2 (de) | 1997-03-26 |
| PL325865A1 (en) | 1998-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9802130A (es) | Agonistas adrenergicos beta3 selectivos. | |
| DK0764632T3 (da) | Selektive beta3-adrenerge agonister | |
| FI953467A0 (fi) | Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja menetelmä niiden valmistamiseksi | |
| DE69939705D1 (de) | Behandlung der pompeschen krankheit | |
| TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
| DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
| FI870219A0 (fi) | Hypoglykemiska tiazolidindioner. | |
| DK0690851T3 (da) | Guanidin-derivater, som er anvendelige til behandling | |
| ATE83659T1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| HUP9700368A2 (hu) | II-típusú diabetes mellitus kezelése amilin agonistákkal | |
| NO972128D0 (no) | 2,2-dikloralkankarboksylsyrer, fremgangsmåte for fremstilling av disse, legemiddel inneholdende disse og anvendelse derav for behandling av insulinresistens | |
| DK0694545T3 (da) | Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder | |
| FI885560A0 (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi | |
| TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. | |
| KR880007070A (ko) | 백내장 치료용 약학 조성물 | |
| IT1288399B1 (it) | Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi | |
| ES2181923T3 (es) | 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina. | |
| ES2109512T3 (es) | Macrolactama (ciclamenol) antiinflamatoria. | |
| CA2236269A1 (en) | Selective .beta.3 adrenergic agonists | |
| RU93008438A (ru) | Способ лечения острых респираторных заболеваний | |
| IT8919215A0 (it) | Dispositivo per la cura chirurgica dell'ametropia. | |
| EA199700053A1 (ru) | Новые применения 2-[n-(1,2-бензизотиазолил-3(2h)он-1,1-диоксид]этил 5-этоксикарбонил-2,4,6-триметил-1,4-дигидропиридин-3-карбоксилата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |